European Commission urged to expand clinical trials initiative focusing on Africa
This article was originally published in SRA
The European Commission is being urged to expand the scope of an EU research and development programme that was set up to accelerate the development of new drugs against HIV/AIDS, malaria and tuberculosis and that focuses on conducting clinical trials in Sub-Saharan Africa1.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.